Comparison · NCT02534844-0cc100f6
Adrabetadex vs Sham Control: Parts A/B: Number of Participants Treated for at Least 6 Months Who Qualified for the Rescue Option
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Adrabetadex vs Sham Control: Parts A/B: Number of Participants Treated for at Least 6 Months Who Qualified for the Rescue Option. Trial comparisons, record NCT02534844-0cc100f6. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02534844-0cc100f6
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0526 | 0.0146 | 0.173 | wilson | |
| Risk in group 2 | 0.111 | 0.031 | 0.328 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0585 | -0.279 | 0.086 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.474 | 0.0724 | 3.1 | log | |
| Odds ratio, group 1 over group 2 | 0.444 | 0.0574 | 3.44 | log | |
| Number needed to treat, for one fewer participant with the outcome on Adrabetadex than on Sham Control | 17.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: sham.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Adrabetadex | Participants received lumbar IT infusions of adrabetadex once every 2 weeks for a total of 52 weeks. | 2 | 38 | OG001 |
| Group 2 | Sham Control | Participants received sham control procedures once every 2 weeks for a total of 52 weeks. | 2 | 18 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Parts A/B: Number of Participants Treated for at Least 6 Months Who Qualified for the Rescue Option
- Description
Participants who manifested significant disease progression according to predefined clinical criteria after treatment of 26 weeks or more had the option to rescue. Number of participants who qualified for the rescue option following a minimum of 26 weeks of treatment were analyzed.
- Time frame
- Baseline up to Week 26
- Population
mITT population included all randomized participants who received at least one treatment (sham or adrabetadex). As per planned analysis, efficacy data were collected and presented by overall randomized treatment assignment (either sham or adrabetadex). These two treatment arms (either sham or adrabetadex) combine data from Parts A and B of the study.
Source ClinicalTrials.gov
Trial
- Title
- VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease
- NCT number
- NCT02534844
- Phases
- PHASE2, PHASE3
- Conditions
- Niemann-Pick Disease, Type C
- Interventions
- Parts A/B: Adrabetadex, Parts A/B: Sham Control
- Lead sponsor
- Mandos LLC
- Results first posted
- 2023-02-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02534844?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02534844-0cc100f6